CBLL
CBLLHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCBLL operates as a medical technology company in the United States. The company carries a $1.04B market cap, placing it firmly in the small-cap category. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
Market Cap
$1.04B
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-16.82
EPS (TTM)
$-1.76
EPS (Fwd)
$-1.61
ROE
-43.9%
ROA
-23.4%
Cash
$129.3M
Total Debt
$21.9M
Free CF
-$33.0M
52W Change
110.5%
Annual Financials
Cash vs Debt
Where CBLL stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, CBLL finished 34.70% above its 150-day moving average ($20.52) and 34.63% above its 200-day moving average ($20.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBLL overbought or oversold?
At the October 16, 2026 close, CBLL's RSI(14) was 70.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CBLL holds $129.3M in cash against $21.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$33.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -43.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $25.9M (2022) to $89.1M (2025), reflecting a 244% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CBLL and its sector.